After Dyne Therapeutics (DYN) announced updates for its DYNE-101 program for myotonic dystrophy type 1, which included the company revising the protocol for the registrational expansion cohort of the ACHIEVE trial to switch to video hand opening time as the primary endpoint, H.C. Wainwright believes an increase in the registrational expansion cohort to 60 allows them to have sufficient powering assumptions for vHOT specifically, and “importantly” allows them to detect trends in other secondary endpoints. The analyst, who believes having vHOT as a primary endpoint for an accelerated approval is “encouraging for Dyne’s clinical and commercial strategy,” has a Buy rating and $38 price target on Dyne shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DYN:
- Positive Outlook for Dyne Therapeutics: Buy Rating Justified by Promising DYNE-101 Trial Results and Strategic Moves
- Dyne at ‘attractive entry point’ following pullback, says Chardan
- Morning Movers: Verve skyrockets after deal to be acquired by Eli Lilly
- Dyne Therapeutics: Strategic Shift to vHOT and FDA Support Bolster Buy Rating
- Dyne Therapeutics pivot on primary endpoint will ‘raise questions,’ says Stifel